Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2019

View Archived Issues

Neutrophils stick with dipeptidase in lung, liver

OncoNano receives grant to support development of oncology product candidate ONM-500

Novel Chemerin GPCR agonist OK-113 exhibits anti-inflammatory activity in DED mouse model

Discovery of a targeted covalent CDK14 inhibitor with a TAIRE kinase-biased selectivity profile

Pulmonary mucormycosis mouse model developed to test treatments

FDA accepts IND for clinical study of MR-301 for severe traumatic brain injury

First patient enrolled in phase IIa study of sepranolone

Immatics and Celgene collaborate to develop novel adoptive cell therapies

La Jolla Pharmaceutical receives European approval for Giapreza

Mirati Therapeutics compounds target the PRC2 EED binding site

Denali Therapeutics synthesizes brain-penetrant LRRK2 kinase inhibitors for the treatment of PD

New antifilarials CBR-417 and CBR-490 validated in models in vivo

Shanghai Dongxi Zhihui Biological Medicine patents beta-amyloid production inhibitors

Preclinical and first clinical data for the novel Ox1R antagonist, JNJ-61393215

NeuracleGenetics describes new programmed cell death protein-1 variants

New DNA-CAR modified T cells presented by Arizona State University

Janssen discloses tau-binding molecules

Beijing Kawin Technology Share-Holding discloses anti-IL-4RA antibodies

Soft sell delivers CRISPR to TNBC

AbbVie discontinues development of Rova-T following phase III MERU findings

ASCLEPIOS I and II trials of ofatumumab in relapsing MS meet primary endpoint

Esperion reports phase II topline results for bempedoic acid/ezetimibe combination tablet

Orinove studies ORIN-1001 in advanced solid tumors and relapsed/refractory metastatic breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...